Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0282646 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Atefeh Deris und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Arak University, Arak, Iran. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Patients with metastatic castration-resistant prostate cancer (mCRPC) are divided into three groups based on their response to Abiraterone treatment: best responder, responder, and non-responder. In the latter two groups, successful outcomes may not be achieved due to the development of drug-resistant cells in the tumor environment during treatment. To overcome this challenge, a secondary drug can be used to control the population of drug-resistant cells, potentially leading to a longer period of disease inhibition. This paper proposes using a combination of Docetaxel and Abiraterone in some polytherapy methods to control both the overall cancer cell population and the drug-resistant subpopulation. To investigate the competition and evolution of mCRPC cancer phenotypes, as in previous studies, the Evolutionary Game Theory (EGT) has been used as a mathematical modeling of evolutionary biology concepts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Science, Arak University, Arak, Iran.
ORCID-Profile: Mahdi Sohrabi-Haghighat
Zitieren
APA
Deris, A., & Sohrabi-Haghighat, M. (2023). Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics. PLOS ONE. https://doi.org/10.1371/journal.pone.0282646
Vancouver
Deris A, Sohrabi-Haghighat M. Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics. PLOS ONE. 2023. doi:10.1371/journal.pone.0282646
BibTeX
@article{Deris2023,
author = {Deris, Atefeh and Sohrabi-Haghighat, Mahdi},
title = {Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0282646}
}
EUVIMED